Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. reports the results of the Annual General Meeting held on June 2, 2026, in Amsterdam, the Netherlands. The meeting addressed governance matters, including the adoption of financial statements for the fiscal year 2025, board appointments, and capital structure amendments.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document confirms that shareholders approved the adoption of the annual accounts for the financial year 2025, but the detailed financial figures contained within those accounts are not disclosed in this report.
Material Changes and Governance Actions
- Board Composition: Dr. Lykke Hinsch Gylvin was appointed as a non-executive member of the Board.
- Committee Structure: Effective June 2, 2026, the Board reconstituted its committees:
- Audit Committee: Bart Filius (Chair), Begona Carreno-Gomez, Theresa Heggie.
- Compensation, Nominating and Corporate Governance Committee: Theresa Heggie (Chair), James Shannon, Bart Filius.
- Research and Development Committee: James Shannon (Chair), Martin Maier, Lykke Hinsch Gylvin.
- Auditor Appointment: KPMG Accountants N.V. was appointed as the external auditor for the financial year 2027.
- Capital Authorization: Shareholders approved an amendment to the Articles of Association to increase authorized capital and authorized the Board to issue and acquire ordinary shares.
Voting Results and Management Commentary
Shareholder approval was secured for all agenda items, though support levels varied:
- Adoption of 2025 Annual Accounts: 99.7% in favor.
- Release of Directors from Liability (2025): 69.5% in favor.
- Appointment of Dr. Gylvin: 99.7% in favor.
- Appointment of KPMG (2027): 99.8% in favor.
- Increase of Authorized Capital: 65.4% in favor.
- Authorization to Issue Shares: 64.3% in favor.
- Authorization to Acquire Shares: 66.7% in favor.
The filing contains no specific management commentary regarding operational outlook, risks, or contingencies beyond the procedural results of the meeting.
Investor Verification Checklist
- Verify the specific financial figures for the 2025 fiscal year in the full annual report, as this filing only confirms their adoption.
- Review the implications of the increased authorized capital and share issuance/acquisition authorizations on potential dilution.
- Assess the impact of the new Board member, Dr. Lykke Hinsch Gylvin, on the Research and Development Committee's strategy.
- Confirm the terms of the engagement with KPMG for the 2027 audit cycle.